The Catalyst

Most Recent Posts

05.24.11

An interesting article in the New York Times health section describes a series of interesting studies that suggest that heart health at middle age is a good indicator of potential risk for future heart disease.

05.20.11 | By Kate Connors

Today, PhRMA released our new overview of the effect that medical advances have had on Americans, finding that new medicines have yielded significant progress in the battle against disease.

05.19.11

Over at Congress Blog today, there is a good piece from Eli Lilly Chairman, president and CEO, John C. Lechleiter on the importance of good trade policies that stimulate innovation.

05.19.11 | By Kate Connors

On Wednesday, Jerry Lewis announced that this year, he will retire as host of the Muscular Dystrophy Association's annual telethon - a position he has filled for 45 years.

05.17.11

Bill Gates and the Bill & Melinda Gates Foundation are in the news again, appealing for a "decade of vaccines" to help strengthen global immunization programs. Their goal is to save an additional 4 million lives by 2015 and 10 million by 2020.

05.17.11 | By Kate Connors

A study in the Proceedings of the National Academy of Sciences - though not an easy read, admittedly - gives hope to some smokers by finding that a genetic variant may make it easier to quit smoking (Time translates it for those who may want a more-readable version).

05.17.11

I want to bring to your attention an interesting story about how the role of patients and patient support organizations are coming to play a bigger role in global health decision-making.

05.13.11

Hoosiers Work for Health, the Indiana chapter of We Work for Health held an event in Southern Indiana earlier this week calling attention to both the contribution that the biosciences make to Indiana's economy and the importance of creating an economic and investment environment in Indiana that promotes growth in the life sciences sector.

05.13.11 | By Kate Connors

Healthcare providers know that no two patients are alike. And just as the saying goes that men are from Mars and women are from Venus, their bodies (and the ways in which they require care) are often worlds apart.

For example, heart attacks plague both genders, but the symptoms often vary. Women often metabolize medicines differently from men in ways that aren't explained simply by differences in body sizes. They are also more prone to diseases like multiple sclerosis, lupus, migraines, osteoporosis and fibromyalgia.

05.12.11

Down in Louisiana, where record flooding is becoming a real threat, Governor Bobby Jindal is recommending that residents who may have to evacuate their homes and communities remember to write down their prescription medicines before they leave their homes.

05.12.11

Battelle, the world's largest independent research organization, is out with a new report on the economic impact of the human genome project. The headline from the report is that the "$3.8 billion investment in the Human Genome Project drove $796 billion in economic impact creating 310,000 jobs and launching the genomic revolution."

The four main conclusions reached in the Battelle study are:

05.11.11

CBS Morning News ran a good piece on the growing problem of counterfeit drugs. It's worth taking a look at. And for more information on the counterfeit drugs epidemic, visit http://www.phrma.org/issues/counterfeit-drugs.

05.11.11 | By Kate Connors

Today was the launch of the Script Your Future campaign, an effort to encourage patients living with chronic diseases to better manage their conditions by taking their medicines as directed.

According to the campaign's Web site, "Understanding your condition and taking your medicine correctly are important steps toward a longer, healthier life. This campaign can help you with tools to manage your medicines."

05.11.11

A piece over at Everyday Health has some good, common sense tips for women concerned about heart disease.

05.09.11 | By Kate Connors

Last Wednesday, I mentioned a Boston Globe article about biopharmaceutical research companies and the emphasis on studying medicines in specific populations, for rare conditions, and more.

In that post, I provided some examples of PhRMA's Medicines in Development Reports, which are a wealth of just this sort of information.

Pages